JP2014515377A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2014515377A5 JP2014515377A5 JP2014512961A JP2014512961A JP2014515377A5 JP 2014515377 A5 JP2014515377 A5 JP 2014515377A5 JP 2014512961 A JP2014512961 A JP 2014512961A JP 2014512961 A JP2014512961 A JP 2014512961A JP 2014515377 A5 JP2014515377 A5 JP 2014515377A5
- Authority
- JP
- Japan
- Prior art keywords
- hcv
- compound
- interferon
- deuterium
- pharmaceutically acceptable
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
- 150000001875 compounds Chemical class 0.000 claims 20
- 229910052805 deuterium Inorganic materials 0.000 claims 11
- YZCKVEUIGOORGS-OUBTZVSYSA-N Deuterium Chemical compound [2H] YZCKVEUIGOORGS-OUBTZVSYSA-N 0.000 claims 8
- 108010050904 Interferons Proteins 0.000 claims 8
- 102000014150 Interferons Human genes 0.000 claims 8
- 229940079322 interferon Drugs 0.000 claims 8
- 150000003839 salts Chemical class 0.000 claims 6
- 239000003814 drug Substances 0.000 claims 5
- 229940124597 therapeutic agent Drugs 0.000 claims 5
- 108010047761 Interferon-alpha Proteins 0.000 claims 4
- 102000006992 Interferon-alpha Human genes 0.000 claims 4
- IWUCXVSUMQZMFG-AFCXAGJDSA-N Ribavirin Chemical compound N1=C(C(=O)N)N=CN1[C@H]1[C@H](O)[C@H](O)[C@@H](CO)O1 IWUCXVSUMQZMFG-AFCXAGJDSA-N 0.000 claims 4
- 229960000329 ribavirin Drugs 0.000 claims 4
- HZCAHMRRMINHDJ-DBRKOABJSA-N ribavirin Natural products O[C@@H]1[C@H](O)[C@@H](CO)O[C@H]1N1N=CN=C1 HZCAHMRRMINHDJ-DBRKOABJSA-N 0.000 claims 4
- -1 deuterium compound Chemical class 0.000 claims 3
- 208000015181 infectious disease Diseases 0.000 claims 3
- 108091032973 (ribonucleotides)n+m Proteins 0.000 claims 2
- UBCHPRBFMUDMNC-UHFFFAOYSA-N 1-(1-adamantyl)ethanamine Chemical compound C1C(C2)CC3CC2CC1(C(N)C)C3 UBCHPRBFMUDMNC-UHFFFAOYSA-N 0.000 claims 2
- 108020005544 Antisense RNA Proteins 0.000 claims 2
- 229940124186 Dehydrogenase inhibitor Drugs 0.000 claims 2
- UFHFLCQGNIYNRP-UHFFFAOYSA-N Hydrogen Chemical compound [H][H] UFHFLCQGNIYNRP-UHFFFAOYSA-N 0.000 claims 2
- HAEJPQIATWHALX-KQYNXXCUSA-N ITP Chemical compound O[C@@H]1[C@H](O)[C@@H](COP(O)(=O)OP(O)(=O)OP(O)(O)=O)O[C@H]1N1C(N=CNC2=O)=C2N=C1 HAEJPQIATWHALX-KQYNXXCUSA-N 0.000 claims 2
- 101710200424 Inosine-5'-monophosphate dehydrogenase Proteins 0.000 claims 2
- 102100040018 Interferon alpha-2 Human genes 0.000 claims 2
- 108010079944 Interferon-alpha2b Proteins 0.000 claims 2
- 102000013462 Interleukin-12 Human genes 0.000 claims 2
- 108010065805 Interleukin-12 Proteins 0.000 claims 2
- 102000000588 Interleukin-2 Human genes 0.000 claims 2
- 108010002350 Interleukin-2 Proteins 0.000 claims 2
- 102000004889 Interleukin-6 Human genes 0.000 claims 2
- 108090001005 Interleukin-6 Proteins 0.000 claims 2
- 102000005741 Metalloproteases Human genes 0.000 claims 2
- 108010006035 Metalloproteases Proteins 0.000 claims 2
- 108060004795 Methyltransferase Proteins 0.000 claims 2
- 101800001019 Non-structural protein 4B Proteins 0.000 claims 2
- 101800001014 Non-structural protein 5A Proteins 0.000 claims 2
- 102000012479 Serine Proteases Human genes 0.000 claims 2
- 108010022999 Serine Proteases Proteins 0.000 claims 2
- 230000005867 T cell response Effects 0.000 claims 2
- DKNWSYNQZKUICI-UHFFFAOYSA-N amantadine Chemical compound C1C(C2)CC3CC2CC1(N)C3 DKNWSYNQZKUICI-UHFFFAOYSA-N 0.000 claims 2
- 229960003805 amantadine Drugs 0.000 claims 2
- 239000003184 complementary RNA Substances 0.000 claims 2
- 230000000694 effects Effects 0.000 claims 2
- 210000002443 helper t lymphocyte Anatomy 0.000 claims 2
- 229910052739 hydrogen Inorganic materials 0.000 claims 2
- 239000001257 hydrogen Substances 0.000 claims 2
- DOUYETYNHWVLEO-UHFFFAOYSA-N imiquimod Chemical compound C1=CC=CC2=C3N(CC(C)C)C=NC3=C(N)N=C21 DOUYETYNHWVLEO-UHFFFAOYSA-N 0.000 claims 2
- 229960002751 imiquimod Drugs 0.000 claims 2
- 230000002452 interceptive effect Effects 0.000 claims 2
- 229940117681 interleukin-12 Drugs 0.000 claims 2
- 229940100601 interleukin-6 Drugs 0.000 claims 2
- 229960000888 rimantadine Drugs 0.000 claims 2
- 229910019142 PO4 Inorganic materials 0.000 claims 1
- 239000003795 chemical substances by application Substances 0.000 claims 1
- 239000003937 drug carrier Substances 0.000 claims 1
- 230000002401 inhibitory effect Effects 0.000 claims 1
- 150000004712 monophosphates Chemical class 0.000 claims 1
- NBIIXXVUZAFLBC-UHFFFAOYSA-K phosphate Chemical compound [O-]P([O-])([O-])=O NBIIXXVUZAFLBC-UHFFFAOYSA-K 0.000 claims 1
- 239000010452 phosphate Substances 0.000 claims 1
- 0 CC(C)(C)[C@@](C(N(C[C@@](C1)Oc2c(cc(cc3)Cl)c3c(**)cn2)[C@@]1C(N[C@](C1)([C@@]1C=C)C(NS(C1(*)CC1)(=O)=O)=O)=O)=O)NC(OC(C)(C)C)=O Chemical compound CC(C)(C)[C@@](C(N(C[C@@](C1)Oc2c(cc(cc3)Cl)c3c(**)cn2)[C@@]1C(N[C@](C1)([C@@]1C=C)C(NS(C1(*)CC1)(=O)=O)=O)=O)=O)NC(OC(C)(C)C)=O 0.000 description 3
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201161490665P | 2011-05-27 | 2011-05-27 | |
| US61/490,665 | 2011-05-27 | ||
| PCT/US2012/039090 WO2012166459A1 (en) | 2011-05-27 | 2012-05-23 | Tripeptides incorporating deuterium as inhibitors of hepatitis c virus |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000498A Division JP2017095487A (ja) | 2011-05-27 | 2017-01-05 | Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2014515377A JP2014515377A (ja) | 2014-06-30 |
| JP2014515377A5 true JP2014515377A5 (enExample) | 2015-06-25 |
| JP6110846B2 JP6110846B2 (ja) | 2017-04-05 |
Family
ID=46201841
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014512961A Expired - Fee Related JP6110846B2 (ja) | 2011-05-27 | 2012-05-23 | Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド |
| JP2017000498A Pending JP2017095487A (ja) | 2011-05-27 | 2017-01-05 | Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017000498A Pending JP2017095487A (ja) | 2011-05-27 | 2017-01-05 | Ｃ型肝炎ウイルス阻害剤としての重水素が導入されたトリペプチド |
Country Status (6)
| Country | Link |
|---|---|
| US (2) | US20130129671A1 (enExample) |
| EP (1) | EP2726475B1 (enExample) |
| JP (2) | JP6110846B2 (enExample) |
| CN (1) | CN103562199B (enExample) |
| ES (1) | ES2650223T3 (enExample) |
| WO (1) | WO2012166459A1 (enExample) |
Families Citing this family (11)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US8957203B2 (en) | 2011-05-05 | 2015-02-17 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| CN103562199B (zh) * | 2011-05-27 | 2016-03-30 | 百时美施贵宝公司 | 作为丙型肝炎病毒抑制剂的掺入氘的三肽 |
| US8691757B2 (en) | 2011-06-15 | 2014-04-08 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| UA119315C2 (uk) | 2012-07-03 | 2019-06-10 | Гіліад Фармассет Елелсі | Інгібітори вірусу гепатиту с |
| ES2613766T3 (es) | 2012-10-19 | 2017-05-25 | Bristol-Myers Squibb Company | Derivados de carbamato de hexadecahidrociclopropa(e)pirrolo(1,2-a)(1,4)diazaciclopentadecinilo sustituidos con 9-metilo como inhibidores de la proteasa no estructural 3 (NS3) para el tratamiento de infecciones del virus de la hepatitis C |
| US9643999B2 (en) | 2012-11-02 | 2017-05-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9334279B2 (en) | 2012-11-02 | 2016-05-10 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9598433B2 (en) | 2012-11-02 | 2017-03-21 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| US9409943B2 (en) | 2012-11-05 | 2016-08-09 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| EP2964664B1 (en) | 2013-03-07 | 2017-01-11 | Bristol-Myers Squibb Company | Hepatitis c virus inhibitors |
| CA2902569A1 (en) | 2013-03-15 | 2014-09-18 | Gilead Sciences, Inc. | Inhibitors of hepatitis c virus |
Family Cites Families (9)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| HU208084B (en) * | 1991-10-31 | 1993-08-30 | Hyd Kutato Fejlesztoe Kft | Process for producing compositions suitable for curing tumorous diseases |
| MY140680A (en) * | 2002-05-20 | 2010-01-15 | Bristol Myers Squibb Co | Hepatitis c virus inhibitors |
| WO2006033012A2 (en) * | 2004-09-24 | 2006-03-30 | Pfizer Limited | Method of screening for modulators of hepatitis c virus infection |
| CN101951770B (zh) * | 2007-12-21 | 2014-12-31 | 阿维拉制药公司 | Hcv蛋白酶抑制剂和其用途 |
| US8202996B2 (en) * | 2007-12-21 | 2012-06-19 | Bristol-Myers Squibb Company | Crystalline forms of N-(tert-butoxycarbonyl)-3-methyl-L-valyl-(4R)-4-((7-chloro-4-methoxy-1-isoquinolinyl)oxy)-N- ((1R,2S)-1-((cyclopropylsulfonyl)carbamoyl)-2-vinylcyclopropyl)-L-prolinamide |
| WO2009108375A1 (en) * | 2008-02-29 | 2009-09-03 | Concert Pharmaceuticals, Inc | Substituted xanthine derivatives |
| US8163921B2 (en) * | 2008-04-16 | 2012-04-24 | Bristol-Myers Squibb Company | Hepatitis C virus inhibitors |
| WO2011038283A1 (en) * | 2009-09-28 | 2011-03-31 | Hoffmann-La Roche Inc. | Novel macrocyclic inhibitors of hepatitis c virus replication |
| CN103562199B (zh) * | 2011-05-27 | 2016-03-30 | 百时美施贵宝公司 | 作为丙型肝炎病毒抑制剂的掺入氘的三肽 |
-
2012
- 2012-05-23 CN CN201280025776.8A patent/CN103562199B/zh not_active Expired - Fee Related
- 2012-05-23 US US13/478,202 patent/US20130129671A1/en not_active Abandoned
- 2012-05-23 WO PCT/US2012/039090 patent/WO2012166459A1/en not_active Ceased
- 2012-05-23 EP EP12725228.6A patent/EP2726475B1/en not_active Not-in-force
- 2012-05-23 JP JP2014512961A patent/JP6110846B2/ja not_active Expired - Fee Related
- 2012-05-23 ES ES12725228.6T patent/ES2650223T3/es active Active
-
2013
- 2013-11-20 US US14/085,358 patent/US20140079664A1/en not_active Abandoned
-
2017
- 2017-01-05 JP JP2017000498A patent/JP2017095487A/ja active Pending